Saatja: ECHAMP - Office <
[email protected]>
Saadetud: 29.06.2020 18:05
Adressaat: Tanel Kiik <
[email protected]>
Koopia: SM Info <
[email protected]>
Teema: ECHAMP Annual Report 2019
Dear Mr Kiik,
We are pleased to attach a copy of ECHAMPs report of activities in 2019.
You may also .Although written in a pre-Covid-19 world, its core messages
remain as valid now as ever before.The European industry for homeopathic
and anthroposophic medicines has been serving patients now for over 200
years and has a strong foundation in EU legislation. The EU institutions
have succeeded in creating a system that allows patients the option of
accessing safe, high quality homeopathic and anthroposophic medicinal
products of their choice. The industry leads the way globally with its
expertise in the manufacture of these products and we can be proud of the
European heritage and global standing of this sector.ECHAMP and our
members work hard to protect the future of this industry; we are
determined to communicate the lasting relevance and value of these
medicines and are committed to strive for greater integration of these
therapies into health care.We continue to seek stronger support at
European and national level, to facilitate an open and objective
discussion on the benefits and potential of these medicines and their
place in a well-functioning, forward-thinking, people-centred health
system that balances curative services with preventive care and self-
care.Now is the time for politicians and policy makers to support our
industry in standing up for the peoples choice for these medicines.We
wish you a safe return to a more normal way of life.Yours sincerely
David Reckeweg-Lecompte Amandine
OsetPresident
Public Affairs Manager
ECHAMP
[email protected]
Rue Washington 38-40B-1050 BrusselsT +32 2 649 94 40to ECHAMP e-
newsPlease consider the environment before printing this email
Annual Report 2019
Support our industry
CHOICE
in standing up for patient
Contents
1 Words from the President David Reckeweg-Lecompte
Homeopathic and anthroposophic medicines –
support our industry in standing up for patient choice
4 A well-regulated sector, an established European industry
8 Pharmacopoeia – Towards a common quality standard
9 Spotlight on an industry
10 The global debate
12 Inside ECHAMP
Words from the President A changing political landscape A long-standing and strong foundation
The industry for
In 2019, the European electorate sent some clear in European law
messages to their politicians and policy makers, The EU institutions have succeeded in creating a
putting pressure on the EU institutions to redefine system that allows patients the option of accessing
homeopathic and
their role in the face of a surge of concern for the safe, high quality homeopathic and anthroposophic
environment. The new Commission has confirmed medicinal products of their choice.
its commitment to implementing the UN goals for This sector has a strong foundation in EU
anthroposophic
sustainable development and has given priority to legislation (see page 4), first established in 1992 to
supporting the Member States in improving the ensure free trade within the European Union and
quality and sustainability of their health systems. freedom of choice for patients while safeguarding
medicines:
This sets a welcome context for our industry, quality and safety. Today, the industry is highly
which can make a valuable contribution towards regulated and the European system ensures the same
meeting these goals. high standards for quality and safety for these as for
Standing up
all medicinal products.
An established, patient-led, In 2017, a report by the Homeopathic Medicinal
sustainable industry Products Working Group of the Heads of Medicines
for patient
The European industry for homeopathic and Agencies substantiated the legitimacy for EU
anthroposophic medicines has been serving patients regulation in this field – all 24 responding EU
now for over 200 years. The industry is, largely, Member States except two (Cyprus and Malta)
choice
defined by the demand from prescribers and confirm the presence of a market for homeopathic
patients for a wide range of products, providing medicinal products and therefore the practice of
millions of EU citizens with their choice in homeopathy in their countries.
healthcare. These medicines can be individually
prescribed by a doctor or practitioner or selected Europe leads the way in a global context
for self-medication for everyday ailments. The European industry continues to lead the way
Companies offer a broad spectrum of products globally with its expertise in the manufacture of
for individual patients, and the homeopathic and anthroposophic medicinal
“We seek stronger industry is characterised by huge products.
support from variety, with thousands of different The 2019 World Health Organisation Global
politicians and starting materials, potencies and Report on Traditional and Complementary Medicine
policy makers to dosage forms required for the (see page 10) confirms the use of homeopathy in 100
facilitate an open proper practice of the therapies. countries around the world. In his foreword, WHO
and objective Despite the broad spectrum Director General, Dr Tedros Adhanom Ghebreyesus,
discussion on the of products, its medicines describes traditional and complementary medicine
benefits and have a negligible as an “…important and often underestimated health
potential of these environmental impact. resource … to help tackle the unique health
medicines.” challenges of the 21st century.” In many countries,
David Reckeweg-Lecompte,
President, ECHAMP
such as India, Mexico, Switzerland, Germany and
Luxembourg, the government’s commitment to
these therapies is clear and strong (see page 11).
The European Commission itself recognises the
importance of ensuring patient choice in this sector,
echamp annual report 2019 1
saying that “The current regulatory framework EU citizens have the fundamental right to
The millions of users for homeopathic products ... strikes a balance access balanced and neutral information to enable
between ensuring their quality and safety ... while them to choose the health care most suited to
of homeopathy and at the same time giving citizens access to these their needs. In the changing global context, the
products.” European political and regulatory conversation
anthroposophic Nevertheless, in countries such as France, risks losing sight of the long-established
Spain, UK and Australia, attacks on this sector are contribution that homeopathy and anthroposophic
medicine do so because resulting in government restrictions on patient medicine make to the health challenges of our
access to these medicines. Such moves fly in the times and the social and economic benefits of
they experience real face of patient preferences and are out of step with these therapies. The European industry and the
the global trend (see page 10). wider sector are determined to communicate the
improvements to their We should be proud of the European heritage lasting relevance and value of these medicines.
and global standing of this sector and work to We are committed to strive for greater integration
health. protect its future. of these therapies into health care.
Standing up for patient choice Looking forward
The millions of users of homeopathy and As ECHAMP moves into 2020 with a new
anthroposophic medicine do so because they management team, the ECHAMP Board of
experience real improvements to their health (see Management warmly thanks former President,
page 9). They are convinced of the benefits, have Dr Gesine Klein and General Secretary, Christiaan
confidence in the high safety profile of these Mol for their dedication and achievements during
medicines and express a high level of satisfaction their terms of office. We continue to build on this
with these treatments. hard work to secure and improve the situation for
Homeopathic and anthroposophic medicinal homeopathic and anthroposophic medicinal
products, currently used in primary and clinical products in the EU.
care across Europe, have an important role to play All parties share responsibility for this work
in the face of major health challenges in the – whether industry, regulator, health professional,
EU. They offer valuable treatment options for policy maker or politician. At ECHAMP, we seek
health challenges such as multimorbidity, stronger commitment at European and at national
polypharmacy, antimicrobial resistance, chronic level, to facilitate an open and objective discussion
and non-communicable diseases and an ageing on the benefits and potential of these medicines.
population. A substantial body of scientific It is time for politicians and policy makers to
research demonstrates the effectiveness of these recognise and acknowledge the patients’
forms of treatment; a growing body of published preference and to support our industry in standing
observational studies confirms their real-world up for the people’s choice for these medicines.
effectiveness. They can contribute to the David Reckeweg-Lecompte took over from Dr Gesine
sustainability of health systems by significantly Klein as President of ECHAMP in June 2019.
reducing treatment costs. In this context, it is
important to ask why, in Europe, is pluralism in
health care not being encouraged?
2 echamp annual report 2019
Photo:
ECHAMP Board
of Management,
The Board of Management is committed to October 2019
securing and improving the situation for
homeopathic and anthroposophic medicinal
products in the EU.
echamp annual report 2019 3
Regulatory environment An established European industry A quick history of regulation of our sector
A well-regulated
This long-standing European industry has a strong
foundation in EU law and has been serving patients In 1992, the Council of the European
now for over 200 years. Legislation for homeopathic Communities stated in the preamble to
Directive 92/73/EEC that homeopathy was
sector, an
medicinal products was first established in 1992
(see inset) with the aim of ensuring free trade within prescribed and used in all Member States.
the European Union and freedom of choice for It directed the Member States to implement
certain changes in their national legislation
established
patients while safeguarding quality and safety.
Today, manufacturers in Europe work to the same to harmonise the market of homeopathic
high quality and safety standards for these as for all products. In 2001, Directive 92/73/EEC was
replaced by Directive 2001/83/EC on the
European industry
medicinal products and there are more than 12,000
registered homeopathic medicinal products in the Community code relating to medicinal
EU Member States and more than 3,000 homeo- products for human use. The intention was to:
pathic medicinal products with a marketing · Create a legal framework that would allow
authorisation. patients access to the medicinal products of
The EU institutions have succeeded in creating their choice provided that all precautions
a system that allows the millions of users of these were taken to ensure the quality and safety.
products the option of accessing safe, high quality · Provide users of these medicinal products
medicinal products of their choice. However, the with a clear indication of their homeopathic
implementation of the current legislative framework character and sufficient guarantees of quality
is still not fully complete in all Member States[1], and safety
which has led to a lack of uniform availability of the
products. · Harmonize the rules relating to the
manufacture, control and inspection
An increasingly complex regulatory environment · Permit the circulation throughout the
ECHAMP works hard to ensure that the specific Community of medicinal products which
characteristics of homeopathic and anthroposophic are safe and of good quality.
medicinal products are taken into account in an It resulted in a special simplified
appropriate way when it comes to new guidelines registration procedure for homeopathic
for our sector, in particular from the European medicinal products without therapeutic
Medicines Agency (EMA) or the Heads of Medicines indications in a pharmaceutical form and
Agencies (HMA). dosage which do not present a risk for the
Although in principal the legislator foresaw patient.
reasonable approaches for these products (see inset), In addition, the standard rules apply to
the actual experience is that the regulatory burden the authorisation of homeopathic medicinal
for the sector is increasing from year to year products with indication. However, the
regarding administrative workload and technical legislation allows Member States to introduce
dossier requirements. or retain in their territory specific rules for the
preclinical tests and clinical trials of these
products. This means they have the option to
recognise the specific characteristics of
[1] Study on the Availability of Medicinal homeopathic medicinal products.
Products for Human Use, Matrix Insight, 2012
4 echamp annual report 2019
2019 activities – quality and safety sector. We hope that it will continue to invest
resources into the work on appropriate
Over a period of time, ECHAMP has given input implementation of regulation for homeopathic
to diverse draft Question and Answer documents and anthroposophic medicinal products and to seek
on quality from the Homeopathic Medicinal further opportunities to enter into dialogue with
Products Working Group of the Heads of Medicines the industry.
Agencies (HMPWG) of the HMA. In 2019, we were
reassured to see that some of our comments have
been accepted by HMPWG, who have adopted final
versions of the Question and Answers documents
on the quality of homeopathic medicinal products.
The direct dialogue with HMPWG in 2018 was
very helpful to foster a shared understanding
of the daily practice of the manufacturing of
homeopathic and anthroposophic medicinal
products and its presentation in the product
dossiers.
However, on the topic of safety assessment
of homeopathic and anthroposophic medicinal
products, the discrepancies regarding the
calculation of first safe dilutions between industry
and the agencies persist. This particularly affects
those products which are on the market in potencies
between mother tincture and D8. ECHAMP
maintains the position that the evaluation criteria
should be based on transparent assessments of The direct dialogue with HMPWG
scientific literature data as applied for conventional
medicinal products. in 2018 was very helpful to foster a
Increasing workload and rising fees shared understanding of the daily
In common with the whole pharmaceutical sector,
our industry is suffering from the increasing practice of the manufacturing of
workload and rising fees for the lifecycle
management of our existing products. This burden homeopathic and anthroposophic
is all the more severe for our sector, where a huge
number of products are needed to keep these medicinal products.
therapies available for patients. The workload and
heavy cost have the effect of preventing companies
from investing in the development of new products
or modern administration forms.
We continue to recognise and appreciate the
work of HMPWG and the effort it invests in this
echamp annual report 2019 5
Pharmacovigilance data and for identifying patterns that suggest new
safety information. It does not lend itself well to It is highly important
Identification of medicinal products the complexity of our industry where we need to
The European Medicines Agency (EMA) is currently distinguish between multiple similar products, for ECHAMP that the
in the process of implementing the standards for example, ‘Echinacea angustifolia’, ‘Echinacea
developed by the International Organization for purpurea’, ‘…extract’ and others, to specify the standards for processing
Standardization (ISO) for the identification of exact grade of dilution or to differentiate between
medicinal products (IDMP). This is done in a plants, plant extracts or drug to solvent relation. The data on the medicinal
phased programme based on the four domains of process quickly becomes too complicated for those,
master data in pharmaceutical regulatory processes: such as our sector, with high numbers of variables products include – where
substance, product, organisation and referential to research. The EudraVigilance web reporting
(SPOR). It is highly important for ECHAMP that application (EVWEB) can be used as an alternative relevant – a harmonised
the standards for processing data on the medicinal but is also too complicated when dealing with high
products include – where relevant – a harmonised numbers of cases. nomenclature which is
nomenclature which is suitable to homeopathic
medicinal products. Special requirements in some Member suitable to homeopathic
ECHAMP has an observer status in this States: Article 16(3) of EU Directive 2001/83/EC
project and also participates in the EMA task force confirms that homeopathic medicinal products medicinal products.
meetings. Due to the relocation of EMA from registered under the special simplified registration
London to Amsterdam, task force activities in procedure (Article 14) (see page 4) are exempt from
2019 were limited. The final version of the EU pharmacovigilance requirements. According to this
Implementation Guide for IDMP/SPOR, the draft legislation, there are no EU reporting obligations
of which was extensively commented by ECHAMP, for suspected adverse reactions for these registered
is expected in the first quarter of 2020. products. In some Member States, certain
obligations continue to exist based on national rules.
Pharmacovigilance requirements:
inconsistent and irregular
The EMA is also responsible for the coordination
of the EU pharmacovigilance system. In 2018, it
was already becoming apparent that changes in the
pharmacovigilance obligations for manufacturers
of homeopathic medicinal products in the EU were
resulting in inconsistent and irregular requirements.
In 2019, the situation remained unchanged.
The following examples illustrate this.
EMA databases: Of concern to ECHAMP members
is the usability of the EudraVigilance Data Analysis
System (EVDAS), the central tool for finding and
receiving individual case safety reports from the
competent authorities, for medicinal product
6 echamp annual report 2019
echamp annual report 2018 7
Pharmacopoeia:
European health policy aims to strengthen A new pilot project
cooperation between Member States in order to An important step forward was made in 2019.
improve access to medicines. On the one hand, After long discussions on the substance
towards a
the pharmaceutical system is related to European monograph work concerning the standard of
policy and on the other hand, it is related to an assay in each monograph, and following the
national laws. To promote availability and access example of colleagues of the traditional Chinese
common quality
to medicinal products, a first step is to ensure medicine group, a pilot project has been set up.
harmonised standards of quality and safety. The Homoeopathic Working Party, which
The European Directorate for the Quality elaborates monographs on the substances used
standard
of Medicines (EDQM) enables the development, in homeopathic preparations, is working on
supports the implementation, and monitors the three pilot monographs: Calendula, Planta tota,
application of quality standards which allow safe Chamomilla, Planta tota, and Arnica, Planta tota.
use of medicinal products. These are also seen The aim is to develop a semi-quantitative high-
as a scientific reference in the rest of the world. performance thin layer chromatography (HPTLC)
It is therefore crucial for homeopathic and as a test. HPTLC is an enhanced form of thin-layer
anthroposophic medicinal products to set chromatography that achieves a higher resolution
quality standards for inclusion in the European and thus allows more accurate qualitative and
Pharmacopoeia. quantitative assessments.
EDQM has been working hard for many Once agreement has been reached on that,
years on the transcription to the European a robust identity and quality test will have been
Pharmacopoeia of the homeopathic manufacturing developed and also a test which allows to measure
methods and the substance monographs from the and monitor stability for important quality
German Homeopathic Pharmacopoeia and the markers that can be measured in relation to
French Pharmacopoeia referring to homeopathic reference substances added in the HPTLC.
manufacturing methods and substance The homeopathic medicines industry is very
monographs. The work has been fruitful and conscious that agreeing on a common quality
common standards have been agreed. standard will further strengthen the strong legal
basis homeopathic medicines have in the EU.
It is crucial for homeopathic and
anthroposophic medicinal products
to set quality standards for inclusion
in the European Pharmacopoeia.
8 echamp annual report 2019
Spotlight
ECHAMP’s new report, Homeopathic and
Anthroposophic Medicinal Products in the EU – Spotlight
on an Industry presents a comprehensive review of
on an industry
the sector, confirming high levels of awareness
of homeopathy and anthroposophic medicine in
many countries in Europe, with growing use of
and demand for these medicines and positive
attitudes of citizens towards these therapies.
Use of The publication provides a unique and
Homeopathy
GERMANY AUSTRIA up-to-date profile of the sector for homeopathic
in the and anthroposophic medicinal products in the
European EU, outlining the demand for these medicinal
56%
of Germans have
62%
used homeopathic of Austrians have used
Union
medicines homeopathic medicines products, presenting the characteristics of this
70% of users are satisfied or very
satisfied with the effectiveness
and lack of side effects industry and summarising the evidence base that As a long-time
underpins their use in health care. It is the only attentive user
such source for summarised EU data on this sector and observer of
BELGIUM and includes the results of detailed research with homeopathic
ECHAMP members over a period of time. medicines, I have
In her foreword to the report, Michèle Rivasi direct personal
69% of Belgian households
use homeopathic
medicines MEP welcomes it as “an authoritative source of experience of the
information.” She confirms her commitment to important role
this sector, saying, “Legislation for homeopathic these therapies
Sales per inhabitant in €
adjusted for GDP per capita
medicinal products has deep roots in their broad play within
and purchasing power standard
(ex-factory prices 2013) use in the Member States. As a long-time attentive complementary
Data not available user and observer of homeopathic medicines, I and integrative
0-2 Sales per
inhabitant have direct personal experience of the important medicine.
2- 4 Sales per
inhabitant
role these therapies play within complementary
Michèle Rivasi, Member of the
4+ Sales per
inhabitant
and integrative medicine. I am committed to European Parliament
ensuring that they take their rightful place within
European health care.”
ECHAMP’s report confirms positive
FRANCE
16%
ITALY
of Italians use BULGARIA attitude and high demand for homeopathic
SPAIN homeopathy at
and anthroposophic medicines.
least once a year
77%
of French
people have
used homeopathy
33% of Spanish have
used homeopathy
69%
trust
homeopathy 64% of family doctors and
pharmacists in Bulgaria
recommend homeopathy
for simple conditions
82%
of users are satisfied or very
satisfied with the outcome
UK
echamp annual report 2019 9
15%
of the British
population have
used homeopathy
The global
The debate around homeopathy and comple- Homeopathy Research Institute tenth
mentary and integrative medicine continues in anniversary
both a European and a global context. In June, David Reckeweg-Lecompte, President
debate
In 2019, a new report from the World Health of ECHAMP, was pleased to attend, along with
Organisation confirms the growth and importance other members of the ECHAMP Board, the 10th
of traditional medicine, including homeopathy. Anniversary celebrations and 4th International
Major scientific and regulatory events, organised Research Conference of Homeopathy Research
by Homeopathy Research Institute and World Institute. Held in London, this was HRI’s biggest
Traditional and Integrative Medicine Forum respectively, cast a and most international conference to date. 352
complementary global spotlight on the sector. attendees from 38 countries enjoyed a fast-paced
medicine is programme as 75 researchers and medics presented
an important World Health Organisation — new report on the very latest research in the field of homeopathy
and often traditional and complementary medicine from 27 countries. In line with the ‘cutting edge’
underestimated A new report from the World Health Organisation, theme of the conference, key topics included
health resource. the Global Report on Traditional and Complementary clinical research, fundamental research, qualitative
Medicine 2019, charts the growth of traditional and research, lab-based studies and veterinary research.
WHO Director General,
Dr Tedros Adhanom
complementary medicine (T&CM) over the past The event will be remembered for the highest
Ghebreyesus twenty years, confirming that homeopathy is the quality scientific programme and as the biggest
third most popular specific complementary event in homeopathy research to date.
medicine after acupuncture and herbal medicine,
used in 100 countries around the world.
In his foreword to the report, WHO Director
General, Dr Tedros Adhanom Ghebreyesus, calls
on policy-makers, health professionals and the
public to capitalise on the potential contribution of
traditional and complementary medicine to “help
tackle the unique health challenges of the 21st
century”, saying that is “…an important and often
underestimated health resource… especially in the
prevention and management of lifestyle-related
chronic diseases, and in meeting the health needs
of ageing populations.” He argues that at a time
when “consumer expectations for care are rising,
costs are soaring, and most budgets are either
stagnant or being reduced”, traditional medicine
should be an option “offered by a well-functioning,
people-centered health system that balances
curative services with preventive care.” HRI London 2019 – 10 Years of HRI
10 echamp annual report 2019
Advancing global collaboration on regulation The sector fights back
In January, ECHAMP helped sponsor the second In many countries, the government’s commitment
World Integrated Medicine Forum in Goa, India, to homeopathy and anthroposophic medicine is
on the regulation of homoeopathic medicinal clear and strong – for example, the investment in
products. The theme was ‘Advancing Global the sector is manifest in India; the Mexican Senate
Collaboration’ and the event was organised by has adopted new legislation regulating home-
the Central Council for Research in Homeopathy, opathic medicine within the context of its new
with the support of the Indian Ministry of Ayurveda, national health service; in the Swiss healthcare
Yoga and Naturopathy, Unani, Siddha and system, homeopathy is on an equal footing with
Homoeopathy (AYUSH). It was opened in person conventional medicine and the German and
by Shri Sripad Yesso Naik, Honourable Minister Luxembourg governments have both recently
of State for the Ministry of AYUSH. Participants confirmed their commitment to upholding access
included representatives from World Health to homeopathy. However, in other countries, it is
Organisation (WHO) and medicines agencies, becoming apparent that attacks on the sector by
pharmacopoeia experts, and industry opponents of homeopathy are resulting in initiatives
representatives from India and around the world. by governments that restrict patient access to these
Despite the growing demand for homeopathic medicines, for example the French government’s
medicines globally, standards for the regulation decision to stop funding the reimbursement of
of these medicines are highly disparate between homeopathic medicinal products, the Spanish
different countries and this directly affects their government’s national plan against what they call
availability. There is an opportunity for the EU, ‘pseudotherapies’ and the decision in June 2018 by
with its expertise in the manufacture and regulation National Health Service (NHS) England to stop
of homeopathic medicines, to endorse its funding homeopathic medicines.
responsibility as global leader in this field and play In 2019, patients and prescribers were more David Reckeweg-Lecompte, President of ECHAMP,
a role in ensuring safety and security for this vocal than ever before, standing up for their right meets Shri Sripad Yesso Naik, Honourable Minister
growing demand. to use the medicines of their choice. More than of State for the Ministry of AYUSH.
Christiaan Mol, then General Secretary of 1.3 million people in France have signed a petition
ECHAMP, gave a strategic perspective on how to in favour of upholding the reimbursement of
advance international collaboration in this field, homeopathic medicines; in response to intense and
presenting different scenarios based on lessons global public pressure to put the record straight,
learnt to date. Australia’s leading research institute, the National
Health and Medical Research Council (NHMRC)
publicly confirmed and clarified that ‘Contrary to
some claims, the [2015 Information Paper on
homeopathy] did not conclude that homeopathy
was ineffective.’
In 2019, patients and
prescribers were more vocal
than ever before.
echamp annual report 2019 11
Inside
Membership Assembly
In April, ECHAMP hosted a lively workshop for
chief and senior executives of the EU industry
ECHAMP
for homeopathic and anthroposophic medicinal
products in Dublin, as part of its annual
Membership Assembly activities. Representatives
from 26 companies across the EU and EFTA and
representatives of some industry associations joined
intensive strategic discussions aimed at helping
frame the future of the sector. The Membership
Assembly itself was chaired by Martin Murray of
New Vistas Healthcare. In recognition of his many
years of involvement, Martin was appointed as
Honorary Member of ECHAMP.
New President, new management
In April, the Board of management of ECHAMP
unanimously elected David Reckeweg-Lecompte to
be its new President, taking over from Dr Gesine
Klein, ECHAMP’s President since 2013. Christiaan
Mol, General Secretary for the same period, also
came to the end of his term. Both Gesine and
Christiaan remain active in the association,
ensuring a smooth transition to the new
management and the continuity of certain projects.
As ECHAMP moves into 2020, the new From left to right:
management team members are settling into their Dr Gesine Klein, David Reckeweg-
roles, with individual board members taking on Lecompte and Christiaan Mol
different responsibilities. The Board of Management
remains determined to build on the hard work of
the previous team and to continue its work to
improve the situation for homeopathic and
anthroposophic medicinal products in the EU.
ECHAMP
Membership Assembly,
Dublin 2019
12 echamp annual report 2019
ECHAMP membership 2019
41 Full Members from 16 different EU Member States plus Norway
and one Extraordinary Member from Switzerland.
Full Member of ECHAMP
Associated Partner of ECHAMP Sweden
Extraordinary Member of ECHAMP Finland
Norway
Estonia
Latvia
Lithuania
Denmark
Netherlands
United
Ireland Kingdom Poland
Germany
Belgium Czech
Republic
Slovakia
France Austria Hungary
Switzerland
Slovenia Romania
Croatia
Italy Bulgaria
Spain
Portugal
Greece
Malta
Cyprus
ECHAMP, the European Coalition on Homeopathic &
Anthroposophic Medicinal Products, is the European
association of companies that work closely together
to ensure that they can meet the demand from users
and prescribers across the EU for these products.
It advocates in favour of an appropriate regulatory
environment for these products in the EU.
ECHAMP E.E.I.G.
Rue Washington 40
B-1050 Brussels
T +32 2 649 94 40
E
[email protected]
www.echamp.eu Printed on Cyclus,
100% recycled with post consumer
waste and no optical bleaching agents
© ECHAMP 2020
16 echamp annual report 2019 Design: www.letterg.co.uk